SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Arcturus Therapeutics Announces Encouraging Interim Phase 2 Results From Arct-810 In Otc Deficiency

Arcturus Therapeutics Holdings Inc NASDAQ:ARCT

ARCT